Pursuant to Regulation 30 read with Part- A of Schedule lll of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Beryl Drugs has informed that the Board of Directors in its Board Meeting held on November 13, 2018 has approved the Unaudited Financial Results of the company for the Quarter/ Half year ended 30th September, 2018.
The above information is a part of company’s filings submitted to BSE.